Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer By Ogkologos - June 11, 2025 500 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the OASIS-4 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Pump Up the Volume: “Priming Agents” May Improve Cancer Liquid Biopsies February 22, 2024 Selpercatinib Shows Durable Efficacy in RET-Altered Thyroid Cancer August 28, 2020 Can Cancer Symptoms Be Mistaken for Menopause? August 26, 2021 What to Expect During a Skin Cancer Screening May 31, 2022 Load more HOT NEWS Clinical Trials in Genitourinary Cancers: MAGNITUDE, PROOF 302, and CYTOSHRINK FDA Approves Tremelimumab in Combination with Durvalumab for Unresectable Hepatocellular Carcinoma Cetuximab Outperforms Durvalumab for Head and Neck Cancer When Cisplatin Isn’t... Adjuvant Immunotherapy Approved for Some Patients with Lung Cancer
